PD-L1基因多态性与结直肠癌患者奥沙利铂化疗疗效和安全性的相关性研究

目的:研究PD-L1/3'-UTR上单核苷酸多态性rs4143815与结直肠癌患者奥沙利铂化疗疗效及安全性的相关性。方法:首先,测定262例接受奥沙利铂化疗的结直肠癌患者rs4143815的基因型;然后,统计分析基因型与奥沙利铂化疗疗效、不良反应发生情况及临床病理参数的相关性。结果:PD-L1/3'-UTR上单核苷酸多态性rs4143815与奥沙利铂治疗的疗效显著相关(P=0.028);与C/C型相比,C/G型患者的化疗疗效更好(OR=2.10),而G/G型患者的疗效却更差(OR=0.49)。然而,G/G型患者的不良反应发生率更低(OR=0.46)。此外,PD-L1/3'-UTR上单核苷酸多态性rs4143815与结直肠癌的肿瘤大小显著相关,G/G型患者的肿瘤体积比C/C型患者更小(R=0.08)。结论:rs4143815与奥沙利铂治疗结直肠癌患者的疗效、安全性和肿瘤大小显著相关,可能成为预测结直肠癌患者奥沙利铂治疗的疗效和安全性的参考分子标志物。

Study on the Relationship between PD-L1 Single Nucleotide Polymorphism and Oxaliplatin-based Chemotherapy Efficacy and Safety of Colorectal Cancer

ABSTRACT Objective: To study the association of single nucleotide polymorphism rs4143815 in PD-L1 3''-UTR with the efficacy and safety of oxaliplatin-based chemotherapy in colorectal cancer(CRC) patients. Methods: The genotypes of rs4143815 were determined in 262 cases of CRC patients treated with oxaliplatin. Statistical analysis was conducted to determine the association of genotypes with oxaliplatin-based chemotherapy efficacy, occurrence of adverse reactions and clinical pathological characteristics. Results: Single nu- cleotide polymorphism rs4143815 in PD-L1 3''-UTR was significantly related to oxaliplatin-based chemotherapy efficacy. Compared with the C/C genotype, patients with C/G heterozygous had better efficacy (OR=2.10), while patients with G/G homozygous achieved poorer response (OR=0.49). However, the incidence of adverse reactions was lower in the patients with G/G compared to the patients with C/C (OR=0.46). Moreover, single nucleotide polymorphism rs4143815 in PD-L1 3''-UTR was significantly related to the tumor size of CRC. The patients with G/G burdened smaller tumors than the patients with C/C(OR=0.08). Conclusion: Rs4143815 was significantly related to the response, safety, and tumor size of CRC patients, it might be may be regarded as a molecular marker to predict the efficacy and safety of oxaliplatin-based chemotherapy for CRC patients.